CRYSTALLINE FORM I OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL) 10H THIENO [2,3-B][1,5]BENZODIAZEPINE

A novel crystalline form of a known substance cannot be characterized in a sufficient clear and concise manner - distinguishing it form prior art compounds - by a vague property ("having a stable colour upon storage at ambient conditions") or by the giving of infrared absorbance bands alon...

Full description

Saved in:
Bibliographic Details
Main Authors THENNATI, RAJAMANNAR, RAJEEV, REHANI BUDHDEV, CHHABADA, VIJAY CHHANGAMAL
Format Patent
LanguageEnglish
French
Published 10.07.2003
Edition7
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A novel crystalline form of a known substance cannot be characterized in a sufficient clear and concise manner - distinguishing it form prior art compounds - by a vague property ("having a stable colour upon storage at ambient conditions") or by the giving of infrared absorbance bands alone. Only the characterisation by certain x-ray powder diffraction peaks seems to be sufficient (and a combination of such peaks with IR absorbance bands). For this reason, claims 1 and 3 (and claims 22-23 as far as they refer to claim 1 or 3) are not searchable. Further, the characterization of a novel product by its preparation process (see product-by-process claims 4-21) is not allowable, because such a characterization is only allowable in cases where no other possibility of characterizing a product is possible (which is not the case for the new compound of the present application).
Bibliography:Application Number: CA20022471341